Note to users. If you're seeing this message, it means that your browser cannot find this page's style/presentation instructions -- or possibly that you are using a browser that does not support current Web standards. Find out more about why this message is appearing, and what you can do to make your experience of our site the best it can be.

Subscribe

Sci. STKE, 6 November 2007
Vol. 2007, Issue 411, p. tw398
[DOI: 10.1126/stke.4112007tw398]

EDITORS' CHOICE

Cancer Therapy A New Angiogenesis Inhibitor

Elizabeth M. Adler

Science's STKE, AAAS, Washington, DC 20005, USA

Although antibodies directed against vascular endothelial growth factor ({alpha}VEGF) can prolong life when given to individuals with certain cancers in conjunction with chemotherapy, inhibition of VEGF signaling can elicit adverse effects and also stimulate the production of alternative angiogenic mechanisms in tumors (see Jain and Xu). Noting that placental growth factor [PIGF, a member of the VEGF family that binds VEGF receptor 1 (VEGFR-1)] is not required for normal development and maintenance of the vasculature but has been implicated in pathological angiogenesis, Fischer et al. investigated the effect on tumors of an antibody directed against PIGF ({alpha}PIGF). {alpha}PIGF inhibited the growth or metastasis or both of various tumors in mice, some of which were resistant to inhibition of VEGFR signaling. Furthermore, {alpha}PIGF enhanced inhibition of tumor growth by the chemotherapeutic agents gemcitabine and cyclophosphamide, as well as the anticancer effects of an antibody directed against VEGFR-2 ({alpha}VEGFR-2). {alpha}PIGF inhibited tumor angiogenesis and lymphangiogenesis, as well as tumor recruitment of proangiogenic macrophages. {alpha}PIGF failed to increase the expression of several proangiogenic genes stimulated by {alpha}VEGFR-2, and it neither mimicked nor enhanced {alpha}VEGFR-2-dependent side effects. Indeed, pregnant mice treated with {alpha}PIGF delivered litters of healthy pups. Thus, the authors hope that {alpha}PIGF might represent a useful addition to the current anticancer armamentarium.

C. Fischer, B. Jonckx, M. Mazzone, S. Zacchigna, S. Loges, L. Pattarini, E. Chorianopoulos, L. Liesenborghs, M. Koch, M. De Mol, M. Autiero, S. Wyns, S. Plaisance, L. Moons, N. van Rooijen, M. Giacca, J.-M. Stassen, M. Dewerchin, D. Collen, P. Carmeliet, Anti-PIGF inhibits growth of VEGF(R)-inhibitor-resistant tumors without affecting healthy vessels. Cell 131, 463-475 (2007). [PubMed]

R. K. Jain, L. Xu, {alpha}PlGF: A new kid on the antiangiogenesis block. Cell 131, 443-445 (2007). [PubMed]

Citation: E. M. Adler, A New Angiogenesis Inhibitor. Sci. STKE 2007, tw398 (2007).



To Advertise     Find Products


Science Signaling. ISSN 1937-9145 (online), 1945-0877 (print). Pre-2008: Science's STKE. ISSN 1525-8882